$1.08
-0.04-3.57%
At Close: -
$1.09
0.010.93%
After Hours: 4:17 PM EDT
15 minutes delayed
BioXcel Therapeutics
BTAINASDAQ
BioXcel Therapeutics (NASDAQ:BTAI) Stock, Analyst Ratings, Price Targets, Predictions
BioXcel Therapeutics Inc has a consensus price target of $8.2, established from looking at the 49 latest analyst ratings. The last 3 analyst ratings were released from Canaccord Genuity, HC Wainwright & Co., and HC Wainwright & Co. on June 27, 2024, May 10, 2024, and April 23, 2024. With an average price target of $9 between Canaccord Genuity, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 725.69% upside for BioXcel Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Canaccord Genuity
HC Wainwright & Co.
B of A Securities
UBS
Truist Securities
1calculated from analyst ratings
Analyst Ratings for BioXcel Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/27/2024 | Buy Now | 542.2% | Canaccord Genuity | Sumant Kulkarni | $7 → $7 | Maintains | Buy | Get Alert |
| 05/10/2024 | Buy Now | 817.43% | HC Wainwright & Co. | Raghuram Selvaraju | → $10 | Reiterates | Buy → Buy | Get Alert |
| 04/23/2024 | Buy Now | 817.43% | HC Wainwright & Co. | Raghuram Selvaraju | → $10 | Reiterates | Buy → Buy | Get Alert |
| 03/18/2024 | Buy Now | 909.17% | HC Wainwright & Co. | Raghuram Selvaraju | → $11 | Reiterates | Buy → Buy | Get Alert |
| 03/14/2024 | Buy Now | 542.2% | Canaccord Genuity | Sumant Kulkarni | $18 → $7 | Maintains | Buy | Get Alert |
| 03/13/2024 | Buy Now | 542.2% | B of A Securities | Geoff Meacham | $8 → $7 | Maintains | Buy | Get Alert |
| 02/21/2024 | Buy Now | 266.97% | UBS | Colin Bristow | $9 → $4 | Downgrade | Buy → Neutral | Get Alert |
| 11/15/2023 | Buy Now | 909.17% | HC Wainwright & Co. | Raghuram Selvaraju | → $11 | Reiterates | Buy → Buy | Get Alert |
| 10/31/2023 | Buy Now | 909.17% | HC Wainwright & Co. | Raghuram Selvaraju | → $11 | Reiterates | Buy → Buy | Get Alert |
| 10/26/2023 | Buy Now | 909.17% | HC Wainwright & Co. | Raghuram Selvaraju | → $11 | Reiterates | Buy → Buy | Get Alert |
| 10/05/2023 | Buy Now | — | Truist Securities | Robyn Karnauskas | — | Downgrade | Buy → Hold | Get Alert |
| 09/13/2023 | Buy Now | 909.17% | HC Wainwright & Co. | Raghuram Selvaraju | → $11 | Reiterates | Buy → Buy | Get Alert |
| 09/08/2023 | Buy Now | 909.17% | HC Wainwright & Co. | Raghuram Selvaraju | → $11 | Reiterates | Buy → Buy | Get Alert |
| 08/28/2023 | Buy Now | 909.17% | HC Wainwright & Co. | Raghuram Selvaraju | → $11 | Reiterates | Buy → Buy | Get Alert |
| 08/23/2023 | Buy Now | 266.97% | Mizuho | Graig Suvannavejh | → $4 | Reiterates | Neutral → Neutral | Get Alert |
| 08/18/2023 | Buy Now | 909.17% | HC Wainwright & Co. | Raghuram Selvaraju | $60 → $11 | Maintains | Buy | Get Alert |
| 08/15/2023 | Buy Now | 266.97% | Goldman Sachs | Corinne Jenkins | $12 → $4 | Maintains | Neutral | Get Alert |
| 08/15/2023 | Buy Now | 266.97% | Mizuho | Graig Suvannavejh | $40 → $4 | Downgrade | Buy → Neutral | Get Alert |
| 08/15/2023 | Buy Now | 2744.04% | Truist Securities | Robyn Karnauskas | $71 → $31 | Maintains | Buy | Get Alert |
| 08/15/2023 | Buy Now | 1734.86% | Canaccord Genuity | Sumant Kulkarni | $76 → $20 | Maintains | Buy | Get Alert |
| 07/17/2023 | Buy Now | — | Guggenheim | Yatin Suneja | — | Downgrade | Buy → Neutral | Get Alert |
| 07/03/2023 | Buy Now | 5404.59% | HC Wainwright & Co. | Raghuram Selvaraju | $66 → $60 | Maintains | Buy | Get Alert |
| 06/30/2023 | Buy Now | 3569.72% | Mizuho | Graig Suvannavejh | → $40 | Reiterates | Buy → Buy | Get Alert |
| 05/30/2023 | Buy Now | 5955.05% | HC Wainwright & Co. | Raghuram Selvaraju | → $66 | Reiterates | Buy → Buy | Get Alert |
| 05/26/2023 | Buy Now | 2193.58% | Goldman Sachs | Corinne Jenkins | $28 → $25 | Maintains | Neutral | Get Alert |
| 05/17/2023 | Buy Now | 5955.05% | HC Wainwright & Co. | Raghuram Selvaraju | → $66 | Reiterates | Buy → Buy | Get Alert |
| 05/11/2023 | Buy Now | 5955.05% | HC Wainwright & Co. | Raghuram Selvaraju | → $66 | Reiterates | Buy → Buy | Get Alert |
| 05/10/2023 | Buy Now | 3569.72% | Mizuho | Graig Suvannavejh | $38 → $40 | Maintains | Buy | Get Alert |
| 05/09/2023 | Buy Now | 4120.18% | Guggenheim | Yatin Suneja | $50 → $46 | Maintains | Buy | Get Alert |
| 03/21/2023 | Buy Now | 5955.05% | HC Wainwright & Co. | Raghuram Selvaraju | $79 → $66 | Maintains | Buy | Get Alert |
| 03/10/2023 | Buy Now | 1918.35% | Jefferies | Chris Howerton | $20 → $22 | Downgrade | Buy → Hold | Get Alert |
| 02/27/2023 | Buy Now | 7147.71% | HC Wainwright & Co. | Raghuram Selvaraju | → $79 | Reiterates | → Buy | Get Alert |
| 02/21/2023 | Buy Now | 7147.71% | HC Wainwright & Co. | Raghuram Selvaraju | $73 → $79 | Maintains | Buy | Get Alert |
| 02/08/2023 | Buy Now | 3386.24% | Mizuho | Graig Suvannavejh | $24 → $38 | Maintains | Buy | Get Alert |
| 01/26/2023 | Buy Now | 2285.32% | Goldman Sachs | Corinne Jenkins | $16 → $26 | Maintains | Neutral | Get Alert |
| 01/03/2023 | Buy Now | 6597.25% | HC Wainwright & Co. | Raghuram Selvaraju | $85 → $73 | Maintains | Buy | Get Alert |
| 12/01/2022 | Buy Now | 1367.89% | Goldman Sachs | Corinne Jenkins | → $16 | Upgrade | Sell → Neutral | Get Alert |
| 11/16/2022 | Buy Now | 1551.38% | Mizuho | Graig Suvannavejh | $19 → $18 | Maintains | Buy | Get Alert |
| 11/11/2022 | Buy Now | 2193.58% | Guggenheim | Yatin Suneja | $28 → $25 | Maintains | Buy | Get Alert |
| 11/11/2022 | Buy Now | 6872.48% | Canaccord Genuity | Sumant Kulkarni | $75 → $76 | Maintains | Buy | Get Alert |
| 11/11/2022 | Buy Now | 1551.38% | Mizuho | Graig Suvannavejh | $19 → $18 | Maintains | Buy | Get Alert |
| 08/24/2022 | Buy Now | 7698.17% | HC Wainwright & Co. | Raghuram Selvaraju | $110 → $85 | Maintains | Buy | Get Alert |
| 07/07/2022 | Buy Now | 1643.12% | Mizuho | Graig Suvannavejh | → $19 | Initiates | → Buy | Get Alert |
| 05/23/2022 | Buy Now | 9991.74% | HC Wainwright & Co. | Raghuram Selvaraju | $134 → $110 | Maintains | Buy | Get Alert |
| 05/09/2022 | Buy Now | 817.43% | Goldman Sachs | Corinne Jenkins | $17 → $10 | Maintains | Sell | Get Alert |
| 04/14/2022 | Buy Now | 12193.58% | HC Wainwright & Co. | Raghuram Selvaraju | $130 → $134 | Maintains | Buy | Get Alert |
| 03/14/2022 | Buy Now | 11826.61% | HC Wainwright & Co. | Raghuram Selvaraju | $140 → $130 | Maintains | Buy | Get Alert |
| 02/16/2022 | Buy Now | 2193.58% | UBS | Colin Bristow | $88 → $25 | Maintains | Buy | Get Alert |
| 11/15/2021 | Buy Now | 2101.83% | Goldman Sachs | — | — | Downgrade | Buy → Sell | Get Alert |
FAQ
What is the target price for BioXcel Therapeutics (BTAI) stock?
The latest price target for BioXcel Therapeutics (NASDAQ:BTAI) was reported by Canaccord Genuity on June 27, 2024. The analyst firm set a price target for $7.00 expecting BTAI to rise to within 12 months (a possible 542.20% upside). 21 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for BioXcel Therapeutics (BTAI)?
The latest analyst rating for BioXcel Therapeutics (NASDAQ:BTAI) was provided by Canaccord Genuity, and BioXcel Therapeutics maintained their buy rating.
When was the last upgrade for BioXcel Therapeutics (BTAI)?
The last upgrade for BioXcel Therapeutics Inc happened on December 1, 2022 when Goldman Sachs raised their price target to $16. Goldman Sachs previously had a sell for BioXcel Therapeutics Inc.
When was the last downgrade for BioXcel Therapeutics (BTAI)?
The last downgrade for BioXcel Therapeutics Inc happened on February 21, 2024 when UBS changed their price target from $9 to $4 for BioXcel Therapeutics Inc.
When is the next analyst rating going to be posted or updated for BioXcel Therapeutics (BTAI)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioXcel Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioXcel Therapeutics was filed on June 27, 2024 so you should expect the next rating to be made available sometime around June 27, 2025.
Is the Analyst Rating BioXcel Therapeutics (BTAI) correct?
While ratings are subjective and will change, the latest BioXcel Therapeutics (BTAI) rating was a maintained with a price target of $7.00 to $7.00. The current price BioXcel Therapeutics (BTAI) is trading at is $1.09, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.